T-cell acute lymphocytic leukemia protein 1 (TAL1)

T-cell acute lymphocytic leukemia protein 1 (TAL1), also known as SCL, is a critical bHLH transcription factor essential for the specification and development of the hematopoietic lineage[1][2][3][5]. It regulates hematopoietic stem cell maintenance, directs mesodermal differentiation into blood cells, and is required for erythroid and megakaryocyte maturation[3][5]. TAL1 achieves these functions by forming multiprotein complexes with E-proteins, LMO1/2, GATA family proteins, and others, controlling lineage-specific gene expression through direct DNA binding. In normal hematopoiesis, TAL1 expression is tightly regulated and silenced during lymphopoiesis; aberrant activation or overexpression (such as by mutation or enhancer activation) leads to a block in differentiation and drives oncogenesis in T-cell acute lymphoblastic leukemia (T-ALL)[2][4][6]. TAL1’s dysregulation is implicated in 40–60% of T-ALL cases, making it a major oncogenic driver and a high-interest molecular target for therapeutic intervention, though direct pharmacological modulators are not yet clinically available. Its essential developmental role means therapeutic targeting requires careful risk assessment to avoid adverse effects on normal blood formation[3][5].

Other names

SCLBHLHA17TCL5Class A basic helix-loop-helix protein 17Stem cell leukemia proteinT-cell leukemia/lymphoma protein 5bHLHa17tal-1

Inhibition or modulation of TAL1 disrupts its oncogenic protein complexes (e.g., with LMO1/2, E-proteins, GATA3), reverses differentiation block, and may arrest cell growth in leukemia[2][3][5].